United Therapeutics CEO Martine Rothblatt Sells $1.06M in Routine 10b5-1 Sale

Insider Transaction Overview

On October 1, 2026, a Form 4 was filed by Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp ($UTHR), reporting indirect sales of common stock executed on September 30, 2026.

• Total Shares Sold: 1,920 shares across 8 tranches
• Price Range: $546.91 to $555.20 (weighted average of ~$550.22 per share)
• Gross Proceeds: ~$1,056,425.10
• Nature of Ownership: Indirect (held by Family Trust)

Plan and Context

• Rule 10b5-1 Trading Plan: These transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan involves the exercise of stock options expiring in March 2027 and sales of the underlying common stock.
• Second of Two Filings: Footnote remarks indicate this submission is the second of two forms filed due to the SEC's 30-line item limitation per table.
• Retained Ownership: Following the reported sales, the specific reporting trust continues to hold 324,443 shares. In addition, Dr. Rothblatt holds 40,513 shares directly, alongside hundreds of thousands of additional shares across other family trusts and spouse holdings.

Significance Assessment

The trading significance is assessed as Low. The disposition represents a tiny portion of Dr. Rothblatt's overall multi-hundred-thousand share position in United Therapeutics and was executed mechanically under a scheduled 10b5-1 plan established in late 2025.